Our Projects

We carry out a wide range of research projects, often in collaboration with partners in academia and in industry. Explore the diverse portfolio of research projects we work on and see how we are delivering global change.

Date

Awarding body

Title

Description

2020

US National Institutes of Health

Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)

LEAP is a Resource Program for long-acting drug delivery that is funded by the US National Institutes of Health and led by Johns Hopkins University in Baltimore. CELT investigators sit on the Executive Board of LEAP and run a modelling and simulation core to support development and implementation of long-acting medicines for HIV, viral hepatitis and tuberculosis treatment and prevention.

2020

Unitaid

Assessing drugs for COVID-19 In early clinical phase Expeditiously (AGILE)

Funding from Unitaid was provided to support seamless phase I/IIa evaluation of candidate drugs to treat SARS-CoV-2 infection and COVID-19 through the AGILE platform trial. Funding also supports CELT investigators in preclinical translation of investigational therapeutics for COVID-19.

2020

Tandem Nano Ltd

Long Acting Therapeutics

This funding supports research on a portfolio of commercial long-acting medicine development activities happening within Tandem Nano Ltd.

2020

Unitaid

LONGEVITY is an exciting and ambitious project that aims to develop long-acting injectable medicines to tackle some of the worlds most devastating infectious diseases. Specifically, CELT researchers are working with colleagues across the globe to develop interventions for malaria chemoprophylaxis, tuberculosis prevention and treatment of hepatitis C virus. Co-funding to establish CELT was also provided through this award.

2019

US National Institutes of Health

Target exposures of rifapentine/rifabutin for long-acting formulations

This funding supports a collaboration between CELT and Johns Hopkins University to better understand the compatibility of tuberculosis treatments with long-acting drug delivery. CELT researchers are providing pharmacokinetic modelling support for empirical research being conducted in Baltimore.

2019

EPSRC

An Injectable Implant Providing Long-Acting Drug Delivery for the Treatment of Chronic disease

This proposal seeks to develop a new drug delivery system that could be easily injected into the body and would provide long-acting drug release. This technology would address issues caused by poor medication adherence. The drug delivery system would be composed of responsive polymer nanoparticles and drug nanoparticles that form a nanocomposite, entrapping a reservoir of drug upon injection into the body. After the drug has been released the materials would degrade into non-toxic components and leave the body.

2018

European Commission

Safety Testing In The Life Cycle Of Nanotechnology-Enabled Medical Technologies For Health (SAFE-N-MEDTECH)

Society and clinical practice pose a growing demand on novel biomaterials, ICT, micro and nanotechnologies for innovative medical devices and in vitro diagnostics (Medical Technologies-MTs). In addition to the challenge of time, the new technologies are subjected to other pressing factors such as qualification, regulation, cost, biocompatibility and the need to be applicable worldwide. SAFE-N-MEDTECH is building an innovative open access platform to offer to companies and reference laboratories, the capabilities, knowhow, networks and services required for the development, testing, assessment, upscaling and market exploitation of nanotechnology-based Medical and Diagnosis Devices. CELT investigators are leading work on the biocompatibility and biodistribution of nano-enabled medical technologies.

2017

European Commission

Regulatory Science Framework for Nano(bio)material-based Medical Products and Devices (REFINE)

REFINE is an international project to improve the regulatory framework for the approval of nano-enabled medical products. REFINE has identified significant biological and technological gaps in the approval framework for nanomedicines, in Europe, and is developing and validating analytical approaches to produce a “smart cascade” based on the biodistribution and biocompatibility testing of candidate materials. CELT investigators are leading work developing new assays investigating, clinically relevant, immunological interactions of nanomaterials, within REFINE.

2017

British Society for Antimicrobial Chemotherapy

In vitro and in vivo assessment of nanoemulsion co-formulations of dolutegravir and rilpivirine.

This project aimed to understand the utility of a type of lipid-based nanoparticle formulation call nanoemulsions for improving the pharmacokinetics of orally administered antiviral drugs.

2015

US Agency for International Development

OPTIMIZE

The OPTIMIZE project was an international collaboration of partners with a shared ambition to optimise the delivery and use of antiretroviral drugs. CELT investigators were specifically involved in development of oral formulations of utility in simplification of adult and paediatric drug delivery.

2015

US National Institutes of Health

Pharmacological Strategies to use the Levonorgestrel Implant in HIV-infected Women

This project underpins a collaboration between CELT investigators and researchers at the University of Nebraska Medical Centre. Specifically, the work aims to determine the impact of pharmacogenetics and drug-drug interactions on the pharmacokinetics of contraceptives delivered via subcutaneous implants.

2015

European Commission

European Nanotechnology Characterisation Laboratory

This, international, infrastructure has been developed to support the development of nanomedicines through to clinical studies. Multiple, non-integrated, providers of characterisation services do not use harmonised assays/technologies to determine physical, chemical and biological characteristics of nanomedicines. EUNCL was created to provide this expertise, using integrated assay cascades, for developers of nanomedicines from academia, SMEs and large pharma to access to accelerate the translation of their lead candidates to clinical studies. CELT investigators are the only UK partners in the EUNCL infrastructure and lead the assays groups on immunological and haematological characterisation of nanomedicines.

 

 

The AGILE clinical trial platform is a new type of study designed for pandemic drug testing which represents a world-first for infectious diseases – capable of testing multiple potential treatments in parallel and speeding up testing by pooling control data across patient groups.
 
Watch our infographic below to find out more; 
 

Back to: Centre of Excellence for Long-acting Therapeutics